Lung Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_35_3664 - Shrinkage of Tumor Volume during Stereotactic Body Radiation Therapy Related to Better Prognosis in Patients with Stage I Non-Small-Cell Lung Cancer

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

Shrinkage of Tumor Volume during Stereotactic Body Radiation Therapy Related to Better Prognosis in Patients with Stage I Non-Small-Cell Lung Cancer
N. Vu; University of Yamanashi Hospital, CHUO SHI, Japan

Purpose/Objective(s): To investigate the inter-fractional tumor volumetric changes during stereotactic body radiation therapy (SBRT) period and their association with the prognosis in stage I non-small-cell lung cancer (NSCLC) patients.

Materials/Methods: A retrospective study of 98 patients diagnosed with stage I NSCLC from January 2006 to December 2008, underwent SBRT with a total dose of 48-50.5 Gy in 4-5 fractions were analyzed. Mean age was 78 years old, and 67% were men. Histology was adenocarcinoma in 51%, squamous cell carcinoma in 24%, and others in 25%. According to the UICC 7th classification, T-stage was T1a in 42%, T1b in 32%, and T2a in 26%. The mean biological effective dose (BED) was 108 Gy with α/β =10. The gross tumor volumes (GTVs) of all patients for each treatment day were obtained by In-room CT based IGRT (CT on-rail). The optimal threshold for distinguishing tumor from pulmonary parenchyma was set up (-700 HU -300 HU) and applied for all GTVs. The GTV in the simulation day was employed as a baseline for comparisons. We examined the association between the change of the tumor volume during SBRT period and the prognosis (overall survival and local control rates).

Results: Median follow-up of these 98 patients was 49 months. Tumor volume (GTV) shrank more than 10% in 22 cases (24.5%); The 5-year local control, and overall survival rates in the group of tumor shrinkage more than 10% were significant higher than those in the group of tumor shrinkage less than 10%, e. g 94.7% vs 70.8%; 85.4% vs 47.6% respectively with the p-value < 0.05 in all of the categories.

Conclusion: The tumor volume has been changed remarkably during SBRT period, and half of patients changed at least 10%. The decrease over 10% in GTV during SBRT treatment was associated with the better prognosis (5-year overall survival and Local control rates) significantly.

Author Disclosure: N. Vu: None.

Send Email for Nam Vu


Assets

TU_35_3664 - Shrinkage of Tumor Volume during Stereotactic Body Radiation Therapy Related to Better Prognosis in Patients with Stage I Non-Small-Cell Lung Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Shrinkage of Tumor Volume during Stereotactic Body Radiation Therapy Related to Better Prognosis in Patients with Stage I Non-Small-Cell Lung Cancer